TY - JOUR T1 - It is time to end our love affair with short-acting β2-agonists in asthma? YES JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00555-2022 SP - 00555-2022 AU - Luis. J. Nannini Y1 - 2022/01/01 UR - http://openres.ersjournals.com/content/early/2022/10/27/23120541.00555-2022.abstract N2 - I read with interest the editorial by Crooks and Faruqi [1]. I agree with almost all of the concepts, however, given my experience, I must question why the scientific community does not take a drastic decision regarding SABA use in asthma. In 2019, Martin and Harrison wrote a similar editorial [2]. SABA overreliance was identified many times as the key issue [3–5]. But nothing happens. SABA's status quo has not been overcome for more than 30 years.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article. ER -